94749-08-3
中文名称
昔美酸沙美特罗
英文名称
Salmeterol xinafoate
CAS
94749-08-3
分子式
C36H45NO7
MDL 编号
MFCD00897708
分子量
603.74
MOL 文件
94749-08-3.mol
更新日期
2024/04/25 17:12:14
94749-08-3 结构式
基本信息
中文别名
苯磺阿曲库铵葛兰素威
2-羟甲基-4-[1-羟基-2-[6-(4-苯基丁氧基)己基氨基]乙基]苯酚 1-羟基-2-萘甲酸盐
沙美特罗羟萘甲酸盐
英文别名
rialSN 408
Siduomi
GR 3343G
Serevent
GR-33343G
Salmetedur
Serevent Diskus
GR 33343X XINAFOATE
SalMeterol Solution
SALMETEROL XINAFOATE
SALMETEROL XINAFONATE
salMaterol xinafoate
Salmaterol Xinafloate
JigMei acid salMeterol
SalMeterol Hydroxynapthoate
SalMeterol Xinafoate Aerosol
Salmeterol hydroxynaphthoate
Salmeterol Xinafoate (150 mg)
SalMeterol-d12 Xinafoate salt
AtracuriuM Besilate IMp. J (EP)
Salmeterol, 1-Hydroxy-2-naphthoate
(+/-) 4-HYDROXY-A1-[[[6-(4-PHENYLBUTOXY)HEXYL]AMINO]M-ETHYL]-1,3-BENZENEDIMETHANOL XINAFOATE
(±)-4-Hydroxy-alpha1-[[[6-(4-phenylbutoxy)hexy])amino]methyl]-1,3-benzenedimethanol xinafoate
4-(1-Hydroxy-2-((6-(4-phenylbutoxy)hexyl)amino)ethyl)-2-(hydroxymethyl)phenol 1-hydroxy-2-naphtho
2-(Hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol 1-hydroxy-2-naphthoate
4-(1-Hydroxy-2-((6-(4-phenylbutoxy)hexyl)aMino)ethyl)-2-(hydroxyMethyl)phenol 1-hydroxy-2-naphthoate
4-Hydroxy-alpha-({[6-(4-phenylbutoxy)hexyl]amino}methyl)-1,3-benzenedimethanol xinafoate, GR 33343X xinafoate
4-Hydroxy-α1-[[[6-(4-phenylbutoxy)hexyl]aMino]Methyl]-1,3-benzenediMethanol 1-Hydroxy-2-naphthalenecarboxylic Acid
GR 33343X xinafoate, (±) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
Salmeterol Xinafoate 2-(Hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol 1-hydroxy-2-naphthoate
4-hydroxy-α1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol with 1-hydroxy-2-naphthalenecarboxylic acid(1:1)
1,3-Benzenedimethanol, 4-hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, 1-hydroxy-2-naphthalenecarboxylate (salt) (9CI)
1,3-Benzenedimethanol, 4-hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt)
2-Naphthalenecarboxylic acid, 1-hydroxy-, compd. with (+-)-4-hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol (1:1)
2-Naphthalenecarboxylic acid, 1-hydroxy-, compd. with 4-hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol (1:1) (9CI)
所属类别
原料药：骨骼肌松弛药物理化学性质
熔点137-138°C
储存条件2-8°C
溶解度H2O: slightly soluble
溶解度H2O：微溶
形态solid
颜色white
Merck14,8337
InChIKeyXTZNCVSCVHTPAI-UHFFFAOYSA-N
安全数据
警示词警告
危险性描述H315-H319-H335
防范说明P280-P271
危险品标志Xi
危险类别码36/37/38
安全说明22-24/25-36-26
安全说明S22-S24/25
WGK Germany3
WGK Germany3
RTECS号QJ1970500
海关编码2922504500
常见问题列表
生物活性
Salmeterol Xinafoate是一种长效的β2-adrenergic receptor激动剂，具有抗炎作用，用于哮喘症状和慢性阻塞性肺疾病（COPD）症状的治疗。靶点
| Target | Value |
| β2-adrenergic receptor |
体外研究
Salmeterol (0.001-25 µM) inhibits human T lymphocyte proliferation.
Cell Proliferation Assay
| Cell Line: | Human T lymphocytes (THP-1 cells) |
| Concentration: | 0.001, 0.01, 0.05, 0.2, 1, 5, and 25 µM |
| Incubation Time: | |
| Result: | The proliferation of Th2 cells was inhibited in a concentration dependent manner. |
体内研究
Salmeterol (0.16 mg/kg), Formoterol (0.32 mg/kg) and combined treatment have therapeutic effects in mice with chronic obstructive pulmonary disease (COPD).
| Animal Model: | Male C57BL/6 mice (6-8 weeks old, body weight: 32-35 g) |
| Dosage: | Salmeterol (0.16 mg/kg) and/or Formoterol (0.32 mg/kg) |
| Administration: | The therapeutic efficacy of co-treatment was investigated in this model over a 56-day-long observation period. |
| Result: | COPD assessment test scores were markedly improved in mice with COPD. |